Welcome to our dedicated page for Inogen SEC filings (Ticker: INGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inogen SEC filings document a respiratory medical technology business that develops, manufactures, markets, sells, and rents respiratory products for homecare use. Results filings and annual proxy materials cover operating performance, executive compensation, director elections, board committees, equity plans, and stockholder voting matters.
Recent Form 8-K disclosures also record share repurchase authorization, leadership and compensatory arrangements, material governance agreements, and Regulation FD communications. The filing record ties these corporate actions to Inogen’s common stock, board oversight, and product portfolio in portable oxygen, airway clearance, stationary oxygen, and CPAP categories.
Inogen, Inc. reported results of its annual stockholder meeting and changes to its equity compensation plan. Stockholders approved an Amended and Restated 2023 Equity Incentive Plan that increases the shares of common stock available for awards by an additional 750,000 shares, effective upon approval.
Two Class III directors, Glenn Boehnlein and Mira Sahney, were re-elected, and Deloitte & Touche LLP was ratified as independent auditor for the year ending December 31, 2026. Stockholders approved executive compensation on an advisory basis and the equity plan, while an amendment to declassify the board was not approved. About 20,844,941 of 27,324,616 entitled shares were represented, a turnout of approximately 76.28%.
Sahney Mira Kirti reported acquisition or exercise transactions in this Form 4 filing.
Inogen director Mira Kirti Sahney received an equity grant of 28,081 shares of Common Stock through a restricted stock unit award. The grant date was June 5, 2026.
The award vests on the earlier of the one-year anniversary of the grant or the day prior to the next Annual Meeting of stockholders, subject to her continued service. After this grant, she directly holds 67,805 shares of Inogen stock. This is compensation-related, not an open-market purchase.
Jamali Vafa reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Jamali Vafa received a grant of 28,081 shares of common stock as a restricted stock unit award on June 5, 2026, at no cash cost. Following the award, Vafa directly holds 43,081 shares. The restricted stock units vest on the earlier of one year after grant or the day before the next annual stockholder meeting, subject to continued service.
Inogen Inc director Glenn S. Boehnlein received an equity grant of 28,081 shares of Common Stock on June 5, 2026, at no cash cost, reported as acquired pursuant to a restricted stock unit award. The award will vest on the earlier of the one-year anniversary of the grant date or the day before Inogen’s next Annual Meeting of stockholders, subject to his continued service. Following this grant, Boehnlein directly holds 104,966 shares of Inogen common stock.
Rider Heather D. reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Heather D. Rider received an equity grant in the form of restricted stock units. She was awarded 28,081 shares of common stock at no purchase price, bringing her directly held stake to 116,282 shares. According to the award terms, these restricted stock units will vest on the earlier of the one-year anniversary of the grant date or the day before Inogen’s next Annual Meeting of stockholders, as long as she continues in service with the company.
Mora Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Elizabeth Mora received 28,081 shares of common stock as a restricted stock unit award. These RSUs were granted at no cash cost and increase her direct holdings to 107,261 shares. The award will vest after about one year, subject to her continued service.
Ladone Mary Kay reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Mary Kay Ladone received a grant of 28,081 shares of common stock through a restricted stock unit award. After this compensation grant, she directly holds 104,966 shares. The RSUs will vest on the earlier of one year from grant or the day before the next annual stockholders meeting, assuming she continues in service.
King Kevin M reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Kevin M. King received a grant of 28,081 shares of common stock through a restricted stock unit award. The award was made at no cash cost per share and is a form of equity compensation rather than an open-market purchase.
Following this grant, King directly holds 104,966 shares of Inogen common stock. According to the award terms, the restricted stock units will vest if he continues serving the company until the earlier of one year from the grant date or the day before the next annual stockholder meeting.
Inogen Inc director Jamali Vafa has filed an initial statement of ownership showing a direct holding of 15,000 shares of Common Stock. This Form 3 indicates Vafa’s beneficial ownership position as of the reporting date, with no buy or sell transactions reported in this filing.
Inogen Inc executive Jennifer M. Yi Boyer, EVP Enterprise Enablement and Chief Human Resources Officer, reported an open-market sale of 10,770 shares of common stock on May 29, 2026. The shares were sold at a weighted average price of $6.5286, within a price range of $6.41 to $6.62.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following this sale, she directly holds 15,977 shares of Inogen common stock.